FlexWave Trial: Efficacy of Extracorporeal Shock Wave Therapy in Post-Stroke Upper Limb Spasticity
Effects of Extracorporeal Shock Wave for Upper Limb Flexor Spasticity in Stroke Patients: A Randomized Controlled Trial
Extracorporeal shock wave therapy (ESWT) has emerged as an effective therapeutic intervention for addressing post-stroke limb spasticity. This research aims to explore the therapeutic implications of focused ESWT for wrist and finger flexor muscles in patients suffering from post-stroke upper limb spasticity.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
This study aimed to evaluate the effects of focused Extracorporeal Shock Wave Therapy (ESWT) on upper limb flexor spasticity in stroke patients. Participants were randomized into two groups: an experimental group receiving targeted ESWT on specific forearm flexor muscles, and a control group receiving placebo treatments mimicking the shockwave therapy, with treatments administered twice weekly over two weeks for a total of four sessions.
The efficacy of the treatment was measured using a comprehensive set of assessment tools, including range of motion, hand grip strength, pain levels, spasticity scales, functional assessments, as well as measures of daily living activities, ultrasound strain elastography. The outcomes were evaluated at multiple points in time: before treatment, and 1, 4, 12, and 24 weeks after the therapy concluded, to assess both immediate and sustained effects of the treatment on upper limb function and spasticity in stroke survivors.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Taipei, Taiwan, 100
- Department of Physical Medicine & Rehabilitation , National Taiwan University Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Individuals aged 18 years or older with unilateral cerebral stroke.
- Wrist/finger flexor muscle tone with a score greater than 1 on the Modified Ashworth Scale.
- Stable medical condition and vital signs.
- Conscious and able to comply with instructions.
Exclusion Criteria:
- History of more than one stroke, traumatic brain injury, or cerebral neoplasm.
- Coexisting central nervous system disorders (e.g., spinal cord injury, Parkinson's disease) or other musculoskeletal diseases affecting muscle tone assessment.
- Contraindications for shockwave intervention, such as malignancies, coagulopathies, local infections, or use of cardiac pacemakers.
- Undergone shockwave therapy or botulinum toxin injections for post-stroke spasticity in the past three months.
- Cognitive, consciousness, or language impairments preventing participation in the intervention or functional assessments.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Focused Extracorporeal Shock Wave Therapy
Participants in this arm will receive focused Extracorporeal Shock Wave Therapy (ESWT) targeting three specific muscles: the flexor carpi ulnaris, flexor carpi radialis, and flexor digitorum superficialis. Each muscle will receive 1,500 shockwave shots per session, accumulating to a total of 4,500 shots across all targeted muscles in each session. The treatment will be administered twice a week for two consecutive weeks, resulting in a total of four treatment sessions. |
The focused shockwaves are directed at the affected muscles in the upper limb, specifically targeting the flexor carpi ulnaris, flexor carpi radialis, and flexor digitorum superficialis. |
|
Placebo Comparator: Placebo-Controlled Shockwave Therapy
Participants in this arm will receive placebo-controlled focused ESWT, mirroring the treatment protocol of the experimental group but without the application of active shockwaves. |
The focused shockwaves are directed at the affected muscles in the upper limb, specifically targeting the flexor carpi ulnaris, flexor carpi radialis, and flexor digitorum superficialis. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
modified Ashworth scale (MAS)
Time Frame: pre-treatment; 1, 4, 12, and 24 weeks post-treatment
|
Evaluate spasticity in individuals with neurological conditions. The scale ranges from 0, indicating no increase in muscle tone, to 4, which represents severe spasticity with affected parts rigid in flexion or extension. |
pre-treatment; 1, 4, 12, and 24 weeks post-treatment
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
modified Tardieu scale (MTS) R2-R1 Angle
Time Frame: pre-treatment; 1, 4, 12, and 24 weeks post-treatment
|
Difference between passive range of motion (R2) and the angle of muscle catch (R1), measured in degrees. Larger values indicate greater dynamic spasticity. |
pre-treatment; 1, 4, 12, and 24 weeks post-treatment
|
|
Tardieu grade
Time Frame: pre-treatment; 1, 4, 12, and 24 weeks post-treatment
|
Spasticity severity (0-5); higher grades indicate greater spasticity. |
pre-treatment; 1, 4, 12, and 24 weeks post-treatment
|
|
passive range of motion for the wrist and finger joints
Time Frame: pre-treatment; 1, 4, 12, and 24 weeks post-treatment
|
the extent to which a joint can be moved without the patient actively participating in the movement |
pre-treatment; 1, 4, 12, and 24 weeks post-treatment
|
|
Medical Research Council (MRC) scale
Time Frame: pre-treatment; 1, 4, 12, and 24 weeks post-treatment
|
grades voluntary muscle strength on a 0-5 ordinal scale |
pre-treatment; 1, 4, 12, and 24 weeks post-treatment
|
|
hand grip strength
Time Frame: pre-treatment; 1, 4, 12, and 24 weeks post-treatment
|
use dynamometer to record the maximum force applied when the patient squeezes it |
pre-treatment; 1, 4, 12, and 24 weeks post-treatment
|
|
Barthel index
Time Frame: pre-treatment; 1, 4, 12, and 24 weeks post-treatment
|
measures a person's daily living abilities, focusing on ten areas of self-care and mobility. Scores range from 0 to 100, with higher scores denoting greater independence. |
pre-treatment; 1, 4, 12, and 24 weeks post-treatment
|
|
Functional Independence Measure (FIM)
Time Frame: pre-treatment; 1, 4, 12, and 24 weeks post-treatment
|
assesses a patient's level of disability and tracks changes over time, with a focus on physical and cognitive functioning across 18 items, scored from 18 (total assistance required) to 126 (fully independent). |
pre-treatment; 1, 4, 12, and 24 weeks post-treatment
|
|
Wolf Motor Function Test (WMFT) Functional ability score
Time Frame: pre-treatment; 1, 4, 12, and 24 weeks post-treatment
|
assess upper extremity function in individuals with neurological impairments, using 15 functional tasks. Scoring is on a 6-point ordinal scale, ranging from 0 ("Does not attempt with upper extremity being tested," indicating severe impairment) to 5 ("Movement appears to be normal," suggesting full functionality). Lower scores indicate greater impairment. |
pre-treatment; 1, 4, 12, and 24 weeks post-treatment
|
|
Action Research Arm Test (ARAT)
Time Frame: pre-treatment; 1, 4, 12, and 24 weeks post-treatment
|
a standardized measure evaluating upper limb motor ability in stroke patients, scoring from 0 (no movement) to 57 (normal arm function). It assesses grasp, grip, pinch, and gross arm movement. |
pre-treatment; 1, 4, 12, and 24 weeks post-treatment
|
|
Fugl-Meyer Assessment for the Upper Extremity (FMA-UE)
Time Frame: pre-treatment; 1, 4, 12, and 24 weeks post-treatment
|
range from 0 (complete paralysis) to 66 (full function), assessing motor recovery in post-stroke upper extremities |
pre-treatment; 1, 4, 12, and 24 weeks post-treatment
|
|
ultrasound assessment
Time Frame: pre-treatment; 1, 4, 12, and 24 weeks post-treatment
|
used strain elastography to assess elasticity of forearm muscles |
pre-treatment; 1, 4, 12, and 24 weeks post-treatment
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Shu-mei Yang, MD, National Taiwan University Hospital
Publications and helpful links
General Publications
- Dymarek R, Taradaj J, Rosinczuk J. Extracorporeal Shock Wave Stimulation as Alternative Treatment Modality for Wrist and Fingers Spasticity in Poststroke Patients: A Prospective, Open-Label, Preliminary Clinical Trial. Evid Based Complement Alternat Med. 2016;2016:4648101. doi: 10.1155/2016/4648101. Epub 2016 Jul 18.
- Cabanas-Valdes R, Calvo-Sanz J, Urrutia G, Serra-Llobet P, Perez-Bellmunt A, German-Romero A. The effectiveness of extracorporeal shock wave therapy to reduce lower limb spasticity in stroke patients: a systematic review and meta-analysis. Top Stroke Rehabil. 2020 Mar;27(2):137-157. doi: 10.1080/10749357.2019.1654242. Epub 2019 Nov 11.
- Yasar E, Adiguzel E, Kesikburun S, Yenihayat I, Yilmaz B, Alaca R, Tan AK. Assessment of forearm muscle spasticity with sonoelastography in patients with stroke. Br J Radiol. 2016 Dec;89(1068):20160603. doi: 10.1259/bjr.20160603. Epub 2016 Oct 25.
- Jia G, Ma J, Wang S, Wu D, Tan B, Yin Y, Jia L, Cheng L. Long-term Effects of Extracorporeal Shock Wave Therapy on Poststroke Spasticity: A Meta-analysis of Randomized Controlled Trials. J Stroke Cerebrovasc Dis. 2020 Mar;29(3):104591. doi: 10.1016/j.jstrokecerebrovasdis.2019.104591. Epub 2019 Dec 31.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neurologic Manifestations
- Musculoskeletal Diseases
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Vascular Diseases
- Cardiovascular Diseases
- Muscular Diseases
- Muscle Hypertonia
- Neuromuscular Manifestations
- Pathological Conditions, Signs and Symptoms
- Signs and Symptoms
- Muscle Spasticity
- Stroke
- Therapeutics
- Physical Therapy Modalities
- Rehabilitation
- Ultrasonic Therapy
- Diathermy
- Hyperthermia, Induced
- Extracorporeal Shockwave Therapy
Other Study ID Numbers
Other Study ID Numbers
- 202309126RIND
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.